PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2017 July 11; 8(28): 45793–45806.
Published online 2017 April 25. doi:  10.18632/oncotarget.17415
PMCID: PMC5542228

Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance

Abstract

Trastuzumab is an antibody-based therapy drug targeting HER2-overexpressing tumors. While it has been proven to be very successful initially, most patients eventually develop resistance to trastuzumab. The mechanism of drug resistance is not well understood. Identifying pathways that mediate trastuzumab resistance will improve our understanding of the underlying mechanism and is crucial for the development of therapeutic strategies to overcome resistance.

Here we report a quantitative proteomics profiling of a trastuzumab-sensitive (T-S) gastric cancer cell line NCI N87 and a trastuzumab-resistant NCI N87 (T-R) subline generated by low-dose, continuous trastuzumab treatment. By identifying proteins differentially expressed in these two cell lines, we show that multiple pathways including mTOR, Wnt, DNA damage response and metabolic pathways are significantly altered. We further confirm by western blotting that protein levels of multiple components of the mTOR pathway, including mTOR, AKT and RPS6KB1, are increased, whereas AKT1S1 is decreased, suggesting the activation of mTOR pathway. Importantly, treatment of AZD8055, an mTOR inhibitor, leads to the decreased phosphorylation levels of mTOR downstream molecules RPS6KB1 at Thr421/Ser424 and AKT at Ser473. Furthermore, AZD8055 also preferentially reduces viability, and inhibits migration and invasion abilities of the T-R cells. Together, our findings indicate that mTOR pathway is among multiple signaling pathways that mediate trastuzumab resistance in NCI N87 T-R cells, and that mTOR inhibitors may be used to treat trastuzumab resistant, HER2-positive gastric cancer tumors.

Keywords: HER2, trastuzumab resistance, mTOR signaling pathway, gastric cancer, LC-MS/MS

INTRODUCTION

Globally, gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer related death [1]. GC is often detected at late stages with few treatment options. One actionable GC biomarker is human epidermal growth factor receptor 2 (HER2 or ErbB2), which is encoded by the ERBB2 gene [2, 3]. It is a member of the HER family proteins and its overexpression has a positive correlation with tumor cell proliferation, adhesion, migration and invasion [4]. Approximately 15~20% of GC cases have ERBB2 DNA amplification along with consistent overexpression of HER2 protein [5, 6]. The aberrant overexpression or activation of HER2 is thought to trigger multiple cellular signaling pathways which drive abnormal cell proliferation, drug resistance and metastasis [4, 7].

Molecular targeting therapy has been deemed a highly effective strategy for cancer treatment. Trastuzumab (Herceptin®), a humanized monoclonal antibody against the extracellular domain of HER2, has been widely used in HER2 positive breast cancer (BC) and GC in combination with chemotherapy in clinical treatment [811]. However, due to the acquired resistance to trastuzumab, the effect is limited. It was shown that only less than 13% of the patients benefitted from the trastuzumab therapy [12, 13].

Several pathways for trastuzumab resistance in GC have been identified. Some genetic mutations may contribute to GC survival independent of the therapeutic targets. For example, the p110a subunit of PI3K (PIK3CA) and c.428T>C (p.V143A) homozygous mutation in exon5 of TP53 gene lead to drug resistance and therefore potentially affect the efficacy of clinical therapy [14, 15]. Activation of HER2 target mutation, up-regulation of the PI3K signaling pathway, accumulation of truncated HER2 receptor, activation of insulin-like growth factor receptor (IGFR) and loss of the PTEN, are among the major pathways identified in BC [1621]. Additionally, activation of crosstalk of HER2 to other molecules such as HER3 and MET leads to subsequent activation of downstream signaling pathways [10, 22, 23]. Activation of alternative pathways, such as amplification or mutation of c-MET and SRC activation, low immune response [17, 24], and overexpression of Cyclin E have also been shown in BC [25]. While some of these pathway alterations are shared by GC, there are also GC-specific mechanisms. Activation of the IL-6/STAT3/Jagged-1/Notch pathways [26], overexpression of FGFR3 and its ligand FGF9 [27], catecholamine-induced β2-adrenergic receptor activation which mediates desensitization by upregulating MUC4 expression [28], activation of STAT3 via upregulation of MUC1 and MUC4 expression [29], are some examples. Comparing to BC, molecular pathways that mediate acquired trastuzumab-resistance in GC is less understood [3032].

While DNA sequencing has been a method of choice in the past to identify activated oncogenic pathways in tumors at genomic level, global proteome profiling by mass spectrometry (MS) has emerged as a powerful tool to characterize proteomics changes [15, 33]. Our lab has developed a fast sequencing (Fast-seq) and a label-free quantification (LFQ) workflow (Fast-quan), by which more than 8,000 proteins can be identified and quantified within 12 hours of MS running time [34, 35]. This workflow allows us to analyze a variety of biological samples with consistent results.

In this study, we performed proteomic profiling of a pair of gastric cancer cell lines consisting of a trastuzumab-sensitive NCI N87 and a trastuzumab-resistant subline derived from NCI N87. We identified differentially expressed proteins and investigated the corresponding signaling pathways by bioinformatics analysis. Additional biochemical and functional validation suggest that the mTOR pathway is activated in T-R cells, implicating the mTOR pathway as a potential molecular target for treating tumors arising from trastuzumab resistance.

RESULTS

Proteomic profiling of NCI N87 T-S and T-R cells

We obtained a pair of T-S and T-R cells as described in [26] from the Shi lab. The T-R cells exhibited marked resistance to trastuzumab compared with the T-S cells (Supplementary Figure 1). Western blotting showed that the HER2 levels in the 2 cell lines were comparable, which was in accordance with the MS data (Supplementary Figure 2A, 2B and 2C). Additionally, T-R cells grew faster than T-S cells (Supplementary Figure 3A), and displayed typical morphology of epithelial to mesenchymal transition (EMT) (Supplementary Figure 3B), implying their higher invasive and metastatic potentials. All these characteristics are consistent with the previous report [26].

To identify signal transduction pathways that mediate trastuzumab resistance, we performed quantitative proteomic profiling of the T-S and T-R cells. As shown in Figure Figure1,1, we performed 4 biological replicates on both cell lines and quantified protein abundance with label-free, intensity-based absolute quantification (iBAQ). We normalized protein loading by taking the fraction of total (FOT) followed by multiplication of 105 to obtain iFOT5. A total of 8201 proteins that were detected with at least 2 unique and high quality peptides (1% false discovery rate (FDR) at the peptide level and Mascot ion score greater than 20) were identified. Among them, 6838 proteins were identified at 1% protein FDR (Figure (Figure2A,2A, Supplementary Table 1), and 5596 were found reproducibly in at least 4 of the 8 experiments (Figure (Figure2A,2A, Supplementary Table 2). These 5596 proteins were used for subsequent statistical and bioinformatics analyses. The high correlation (r >0.8) of each pair of the 4 replicates demonstrated a good reproducibility of our measurements (Figure (Figure2B).2B). A principal component analysis (PCA) showed that the T-S and T-R data sets were well separated, and four biological replicates of each cell line were well-clustered (Figure (Figure2C).2C). The distribution of fold changes was shown in a histogram (Figure (Figure2D2D).

Figure 1
A schematic diagram of experimental workflow
Figure 2
A workflow of the whole cellular extracts and identification of differentially expressed proteins

Enrichment analysis of differentially expressed proteins and pathways

We performed student's t tests to identify differentially expressed proteins that were statistically significant. As illustrated in the volcano plot (Figure (Figure3A,3A, Supplementary Table 3), the abundance of 118 proteins (2.1% of the proteome) showed more than twofold increase in T-R cells (p value <0.05, marked as red dots), whereas 84 proteins (1.5% of the proteome) showed more than twofold decrease in T-R cells (p value <0.05, marked as blue dots). The remaining 5394 proteins (96.4% of the proteome) were considered as not significantly changed. Seven differentially expressed proteins that were identified with 1-3 spectrum counts (PSMs) were manually validated (Supplementary Figure 4). The differentially expressed proteins were analyzed by gene ontology (GO) terms enrichment analysis using the WEB-based Gene Set Analysis Toolkit (http://bioinfo.vanderbilt.edu/webgestalt/option.php) [36]. The enrichment of increased or decreased proteins in cellular component, biological process and molecular function are shown in Figure Figure3B3B and and3C,3C, respectively. Proteins that are increased in T-R cells are annotated as localized in extracellular region, macromolecular complex, and membrane-bounded organelle, whereas those decreased in T-R cells are annotated as residing in extracellular region, intracellular part and cell periphery. As for biological processes, increased proteins include those involved in regulation of Rho-Rac GTPase activity, Rho-Rac protein signal transduction and metabolic process, and decreased proteins were primarily shown as cellular response to stimuli, epithelial development and regulation of transport. As to molecular functions, the increased proteins are enriched in transferase activity, ion binding and phosphatase activity, whereas the decreased proteins function in protein binding, catalytic activity and cargo receptor activity. We employed the STRING database (http://string.embl.de/) [37] to build a network of the differentially expressed proteins using high confidence (scores >0.7) expressions and visualize the resulting network using Cytoscape (v3.4.0). We found that AKT, mTOR and CDK4 represent three main hubs formed by up-regulated proteins, and AKT1S1, CASP8 and SDC1 represent three primary hubs formed by down-regulated proteins (Figure (Figure3D).3D). Enrichment analysis showed that several key cancer signaling pathways are activated in T-R cells, with main interaction nodes formed by components of mTOR, Wnt, p53, metabolic and B cell receptor signaling pathways (Figure (Figure3E).3E). A quantitative representation of these proteins is illustrated in the heat map (Figure (Figure3F3F).

Figure 3
Bioinformatics analysis of differentially expressed proteins and pathways

Quantitative proteome profiling uncovers the activation of mTOR signaling pathway in trastuzumab-resistant cells

Among the activated pathways in T-R cells, the over-representation of mTOR pathway components caught our attention. MS identified 30 proteins associated with mTOR pathway (Supplementary Table 4_D1), and several key signaling molecules, such as mTOR, AKT, RPS6KB1, RPS6KA1, MLST8 and AKT1S1, showed significant changes in abundance (Figure (Figure4A,4A, Supplementary Table 4_D2). These signaling molecules were represented by a network diagram of mTOR pathway (Figure (Figure4B).4B). Next, we confirmed the altered expression of mTOR, AKT, AKT1S1 and RPS6KB1 by western blotting (Figure (Figure4C).4C). Quantification of the western blot by densitometry revealed significant changes of these proteins between T-S and T-R cells (Figure (Figure4D).4D). As shown in the protein-protein interaction network (Figure (Figure5A),5A), mTOR represents a major hub in the network involving the 30 proteins, and 6 differentially expressed proteins (mTOR, RPS6KB1, AKT, AKT1S1, MLST8 and RPS6KA1) form the core of the network with high interaction confidence scores (Figure (Figure5B).5B). WEB-based Gene Set Analysis Toolkit revealed that these 6 mTOR pathway proteins are associated with multiple pathological conditions. The top 7 cancer relevant processed with the most significant p values include tuberous sclerosis, neoplasm invasiveness, drug resistance, neoplasms, neoplasm metastasis, tumor angiogenesis and stress (Figure (Figure5C).5C). Protein-protein interactions derived from the STRING database demonstrated that these proteins participate in several signaling pathways such as mTOR, senescence and autophagy, MAPK, insulin, ErbB and IL-5 pathways (Figure (Figure5D5D).

Figure 4
Validation of differentially expressed mTOR pathway proteins
Figure 5
Bioinformatic analysis of differentially expressed proteins involved in mTOR pathway

AZD8055 reduces trastuzumab-resistant cells viability, phosphorylation of RPS6KB1 and AKT in T-R cells

AZD8055 is a novel ATP-competitive mTOR kinase inhibitor that acts on the PI3K/AKT/mTOR pathway to inhibit cancer cell proliferation and/or induce cancer cell death. It has displayed remarkable ability to target a variety of human cancer cell lines through the inhibition of mTORC1/2 signaling, resulting in a better molecular effect than rapamycin [3840]. It is currently being assessed, alone or in combination, in phase I clinical trials in oncology [41, 42]. To test the inhibitory effect of AZD8055 on mTOR pathway in GC cells, we treated T-S and T-R cells with increasing concentrations of AZD8055 for 48 h and measured cell viability. AZD8055 suppressed both T-S and T-R cells in a dose-dependent manner, but the effect was more pronounced in T-R cells at all dosages. While the moderate difference was insignificant at 25 and 50 nM (p>0.05), it was statistically significant at 100 nM with the cell viability of 67.7% and 52.3% for T-S and T-R, respectively (p<0.05) (Figure (Figure6A).6A). A similar trend was observed when cells were treated with higher dosages (p<0.01) (Figure (Figure6A).6A). These results showed that T-R cells appeared to be more susceptible to mTOR inhibition by AZD8055 than T-S cells at concentrations above 100 nM, consistent with its stronger dependence on mTOR pathway for survival. To confirm the pathways that mediate trastuzumab resistance, we performed western blotting to examine the phosphorylation levels of RPS6KB1 at Thr421/Ser424 and AKT at Ser473, which are known signaling events in the mTOR pathway. As anticipated, p-RPS6KB1(Thr421/Ser424) and p-AKT(Ser473) were higher in T-R cells than in T-S cells, and the decrease of p-RPS6KB1(Thr421/Ser424) in T-R cells after AZD8055 treatment was more pronounced between 50 and 200 nM, but was not significantly different at 800 nM (Figure (Figure6B).6B). A similar trend was also observed in p-AKT(Ser473) (Figure (Figure6B).6B). Moreover, immunofluorescence of p-RPS6KB1(Thr421/Ser424) also showed similar results as the western blot (Figure (Figure6C).6C). Taken together, our results strongly suggest that mTOR pathway is activated in T-R cells, which could be preferentially inhibited by AZD8055.

Figure 6
An mTOR inhibitor AZD8055 preferentially inhibited proliferation and phosphorylation levels in NCI N87 T-R cells

AZD8055 inhibits the migration and invasion of trastuzumab-resistant cells

Cancer cells often display high migration and invasion abilities after acquiring drug resistance. Here we evaluated how AZD8055 inhibits migration and invasion of T-S and T-R cells by transwell assays. In the absence of AZD8055, more T-R cells passed through the polycarbonate membrane than T-S cells (p<0.05); however, in the presence of AZD8055, migration of T-R cells was inhibited (p<0.05), whereas migration of T-S cells was not noticeably inhibited (p>0.05) (Figure (Figure7A).7A). Similarly, the higher invasion ability of T-R cells was also significantly inhibited by AZD8055 (p<0.05) (Figure (Figure7B).7B). Our results suggest that activation of mTOR pathway promotes migration and invasion in vitro in T-R cells, and AZD8055 can preferentially block the mTOR pathway in T-R cells.

Figure 7
AZD8055 effect on migration and invasion ability of T-S and T-R cells

DISCUSSION

HER2 gene amplification and protein over-expression is a driver for malignant transformation, and is associated with poor prognosis and drug resistance [43, 44]. Although trastuzumab represents one of the most successful anti-HER2 antibodies in GC therapy, its therapeutic efficacy is proven to be limited due to acquired drug resistance. While mRNA sequencing has been widely used in identifying transcriptional alterations, increasing evidence suggests that the correlation between protein and mRNA is poor. Clearly if one searches for actionable drug targets, measuring protein is more effective than measuring mRNA. Recent advancement in mass spectrometry instrumentation and method has made proteome profiling a feasible approach. Here, we employed quantitative proteomic profiling strategy to identify pathways that mediate trastuzumab resistance. Our data indicate that multiple mTOR pathway components are expressed at elevated levels in T-R cells, suggesting that mTOR activation plays a crucial role in supporting T-R cell proliferation when HER2 is inhibited.

mTOR is the key component in this pathway and is the target of rapamycin. AKT is the main upstream activator of mTOR, and its activation relieves the inhibitory effects of the TSC1-TSC2 complex on Rheb and mTORC1, thereby activating mTORC1 in response to growth factor stimulations. Activated mTORC1 in turn phosphorylates RPS6KB1, a mediator of protein translation and cell growth. In contrast, AKT1S1, a negative regulator of mTOR, showed a decrease in abundance, suggesting that it may function synergistically with AKT on mTOR activation [45, 46]. Previous studies and current data demonstrate that increased cell proliferation, migration and invasion are characteristics of T-R cells [47, 48]. It is perhaps not surprising that inhibition of mTOR can block the cell migration and invasion, as multiple mTOR effectors are key players in these processes [46, 49] and Rho-Rac signaling is the highest ranking upregulated molecular processes by p-value in T-R cells (Figure (Figure3A).3A). It is interesting that, under our experimental conditions, AZD8055 treatment did not seem to cause noticeable blockage of migration and invasion in T-S cells. This result alone does not suggest that mTOR inhibition had no effect for T-S cells, as the dosage and treatment time may need to be optimized. Rather, our results suggest that, among the multiple activated oncogenic pathways, mTOR has become the dominant one that the T-R cells are addicted to for growth and survival, and that targeting this pathway is highly effective.

Our in vitro study demonstrated that mTOR inhibition may be considered as a potential treatment strategy for trastuzumab-resistant GC, and mTOR inhibitors in combination with trastuzumab may prevent or delay clinical resistance and improve the efficacy of trastuzumab in GC. Our study also revealed that several other signaling pathways are associated with trastuzumab resistance, which include Wnt pathway, cell cycle, ECM-receptor interaction and metabolic pathway. It has been reported that Wnt pathway can lead to transactivation of EGFR and EMT-like transition, and causes trastuzumab resistance in HER2 overexpressed BC cells [50]. This is consistent with the result presented in a previous study that resistant cells exhibited typical EMT-like phenotype [26]. Admittedly, our exploratory proteomics studies only provide a starting point for a better understanding of the trastuzumab resistance. As the aforementioned pathways can also be targeted for inhibition, a combinatorial therapy targeting multiple pathways can be explored to overcome trastuzumab resistance in the future.

MATERIALS AND METHODS

Cell lines and cell culture

Human gastric cancer cells T-S and T-R were kindly provided by the Institute of Basic Medical Sciences Dr. Shi. The cells were cultured in Dulbecco's modified Eagle's Medium (DMEM, Gibco®, USA) containing 10% (v/v) fetal bovine serum (FBS) (Gibco®, USA), 1% penicillin/streptomycin (100U/mL) at 37°C in a humidified atmosphere with 5% CO2. T-R cells were cultured in the same media containing 10μg/mL trastuzumab throughout the study period.

Chemicals and antibodies

Trastuzumab (Roche Pharmaceutical Ltd., Switzerland) was solubilized in sterile water containing 1.1% benzyl alcohol (stock solution at 100μg/mL, stored at 4°C). Chemicals used are as follows: AZD8055 (Medchem express, USA), dimethyl sulfoxide (DMSO) (Amresco, USA), Dithiothreitol (DTT) and iodoacetamide (IAA) (Sigma-Aldrich, USA), DAPI (Beyotime Biotechnology, China). Cell Count kit-8 was purchased from Dojindo (Kumamoto, Japan). Antibodies against the following proteins were used for immunoblotting: HER-2 (Abcam, UK), mTOR (Abcam, UK), AKT1S1 (Abcam, UK), RPS6KB1 (Cell Signaling Technology, USA), p-RPS6KB1 (Thr421/Ser424) (Cell Signaling Technology, USA), AKT (Cell Signaling Technology, USA), p-AKT(Ser473) (Cell Signaling Technology, USA), β-actin (Cell Signaling Technology, USA). Horseradish peroxidase-labeled goat anti-rabbit and anti-mouse secondary antibodies were purchased from ZSGB-BIO (Beijing, China).

Protein extraction and peptide separation

Cells were lysed in lysis buffer (8M Urea, 100mM Tris Hydrochloride, pH=8.0) containing 1×protease and phosphatase inhibitors (Thermo Fisher Scientific) for 10 min at 0°C, followed by sonication for 1 min (2s on and 2s off, amplitude 25%). The lysates were centrifuged at 16,200 g for 10 min at 4°C, and the supernatants were collected as whole cell extracts (WCE). Protein concentration was determined by Bradford protein assay (ComWin Biotech Co., Ltd, China). One hundred microgram (100μg) protein from each sample was reduced with 10 mM DTT at 56°C for 30 min and alkylated with 10 mM IAA at room temperature in the dark for additional 30 min. Then proteins were digested using the FASP method with trypsin at 37°C in an orbital incubator [51]. Tryptic peptides were separated with a home-made reverse-phase C18 column and eluted using acetonitrile of different percentage as 6%, 9%, 12%, 15%, 18%, 21%, 25%, 30% and 35% (acetonitrile in 10mM NH4CO3, pH=10). The nine fractions were combined to six fractions (6%+25%, 9%+30%, 12+35%, 15%, 18% and 21%) and dried in a vacuum concentrator.

LC-MS/MS analysis

An Orbitrap FUSION mass spectrometer (Thermo Fisher Scientific) interfaced with an Easy-nLC 1000 nanoflow LC system (Thermo Fisher Scientific) was used for MS analysis. The dried peptides were dissolved in solvent A (0.1% formic acid in water) and loaded to a C18 reversed-phase column (pre-column: particle size, 3μm, pore size, 120Å, 2cm×100μm, home-made; analytical column: particle size, 1.9μm, pore size, 120Å, 12cm×150μm, homemade) at a flow rate of 600 nL/min for 75 min with a linear gradient of 7~35% mobile phase B (0.1% formic acid in acetonitrile). The MS full scan was processed in the Orbitrap from m/z 300 to 1,400 with a resolution of 120,000 at 200 m/z. The most intense ions in each scan under top-speed mode were automatically selected in Quadrupole with a 1.6 m/z window and fragmented by higher energy collision-induced dissociation (HCD) with normalized collision energy of 35%, then measured in the linear ion trap. Automatic gain control (AGC) targets were 5e5 ions with a max injection time of 50 ms for full scans and 5e3 with 35ms for MS/MS scans, dynamic exclusion time was employed for 18s. Data were acquired using the Xcalibur software (Thermo Fisher Scientific).

Protein identification and quantification

The acquired MS/MS spectra were searched by Mascot 2.3 (Matrix Science Inc.) implemented on Proteome Discoverer 2.0 or 2.1 (Thermo Fisher Scientific) against the human National Center for Biotechnology Information (NCBI) Refseq protein databases (updated on 04-07-2013, 32,015 protein entries). The parameter settings were as follows: the mass tolerances were 20 ppm for precursor and 0.5 Da for product ions from FUSION. Up to two missed cleavages were allowed for protease digestion, and the minimal required peptide length was set to seven amino acids. The search engine set cysteine carbamidomethylation as a fixed modification and N-terminal acetylation, oxidation of methionine as dynamic modifications. Precursor ion score charges were limited to +2, +3, +4, +5 and +6. The data were searched against a decoy database so that protein identifications were accepted at FDR of 1%. Label-free protein quantifications were calculated using a label-free, iBAQ approach [52]. A protein's iBAQ divided by the total iBAQ of all identified proteins in one sample was used to define FOT, which was used to estimate the normalized protein abundance and then multiplied by 105 to obtain iFOT5 for the ease of presentation.

Proteome data filtering and statistical analysis

The proteins that were used for further statistical analysis had to be detected in at least 4 of 8 experiments. The differentially expressed proteins were selected by the following rules: protein abundance ratio ≥ 2, or ≤0.5 for up- or down-regulated, respectively, and p value <0.05 using paired two-tailed student test. GO term enrichment analysis was done using WebGestalt website. All identified proteins were defined as background. Protein-protein interaction network analysis was performed using the STRING with interaction sources from experiments and databases and the interaction score set to high confidence (scores > 0.7), the results were displayed using Cytoscape software.

Cell proliferation assays

Cell proliferation was measured with Cell Count kit-8 in accordance with the manufacturer's instructions. In brief, cells were seeded into 96-well plates in 100μL culture medium at a density of 5,000 cells/well and incubated for 24 h at 37°C. Cells were subsequently incubated with or without AZD8055 at the indicated concentrations (0, 25, 50, 100, 200, 400 and 800 nM) with appropriate vehicle control (DMSO) as a substrate. At 48 h post-treatment, 10% Cell Count kit-8 was added to each well, and the cells were further incubated for 3 h at 37°C. Absorbance was measured at 450 nm using an iMark microplate reader (Bio-Rad, USA). All experiments were done in triplicates and repeated three times.

Western blotting

Cells were harvested at 70~80% confluence, and washed twice with cool PBS. Whole cell lysates were extracted using 8M urea containing 1×protease and phosphatase inhibitor for 10 min at 0°C. Lysates were clarified by centrifugation at 16,200g for 20 min at 4°C, and the supernatants were collected as WCE. Protein concentration was determined by Bradford protein assay. A total of 20μg proteins were boiled for five minutes in Laemmli buffer and resolved by SDS-PAGE. Proteins were transferred onto nitrocellulose membrane and blocked with 5% skim milk in TBS-T (10 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH7.4) for one hour. The membrane was incubated overnight at 4°C with primary antibodies followed by TBS-T wash for 5 times, and incubated with horseradish peroxidase-labeled secondary antibody for one hour at room temperature. Proteins were visualized with enhanced chemiluminescence detection reagent.

Cell migration and invasion assays

Migration and invasion assays were performed using 24-well TranswellTM plates containing polycarbonate filters with an 8-μm pore size (Coring Inc., USA). Five hundred microliter (500μL) of complete DMEM medium was then placed in the lower chamber in the presence or absence of AZD8055 (100nM) or 0.1% DMSO (as control), and 2×104 cells/well suspended in 200μL DMEM without FBS were seeded into the upper chamber. Cells were incubated in a humidified incubator at 37°C for 16 h (for migration assay) or 24 h (for invasion assay), respectively. Un-migrated cells on the upper surface of the membrane were scraped off with a cotton swab, and the migrated cells adhering to the underside of the insert were fixed with formaldehyde for 20 min, stained with 0.1% crystal violet for 20 min at room temperature and then visualized under a microscope (OLYMPUS, BX53, Japan). Cells in six independent symmetrical visual fields were counted at 100 × magnification for quantification of the migration potential. For the invasion assay, the upper chamber was inserted with membranes coated with 80μL Matrigel-matrixTM (BD Discovery Labware, USA), and the bottom one was filled with DMEM containing 10% FBS. Cells on the membranes of inserts were fixed, stained, photographed and counted similarly to the migration assay. Each experiment was performed in three replicates.

Immunofluorescence analysis

Immunofluorescence analysis was performed after 24 h cell culture. Cells were washed 3 times in PBS containing 1‰ tween-20 for 5min, and fixed in 4% paraformaldehyde for 20 min and permeabilized in 0.5% Triton X-100 for 20 min at room temperature. Cells were washed 3 times and blocked in 1% BSA for one hour. Subsequently, cells were incubated with primary antibody overnight at 4°C. After washing, cells were incubated with secondary anti-rabbit IgG antibody conjugated with Alexa 594 (ZSGB-BIO, China) for 30 min at 37°C. Nuclei were stained with 1μg/mL DAPI (4′,6-diamidino-2-phenylindole) for 5 min. Finally, cells were visualized under a laser-scanning confocal microscope (Nikon Ti-E, Japan) for image acquisition. The experiments were repeated in duplicate.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES

Acknowledgments

The authors would like to thank all the individuals who have participated in this study. In particular, we are thankful to Dr. Ming Shi for providing cell lines, Dr. Lei Song, Dr. Wenchuan Leng and Kai Li for their helpful discussions and technical assistance.

Abbreviations

T-R
Trastuzumab-resistant
T-S
Trastuzumab-sensitive
GC
gastric cancer
BC
breast cancer
mTOR
mammalian target of rapamycin
LC-MS/MS
liquid chromatography-tandem mass spectrometry
MS
mass spectrometry
WCE
whole cell extracts
FDR
false discovery rate
iBAQ
intensity based absolute quantification
FOT
fraction of total
LFQ
label-free quantification
PCA
principal component analysis
GO
gene ontology
EMT
epithelial-mesenchymal transition

Footnotes

Contributed by

Author contributions

Y Wang, J Qin, and X Xia designed and directed the research; W Liu performed the research and analyzed data; M Liu provided reagents. W Liu, J Chang, and Y Wang wrote the manuscript; Dr. Jiangbei Yuan and Dr. Jinqiang Zhang contributed to revisions.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

FUNDING

This work is supported in part by National Program on Key Basic Research Project (973 Program, 2014CBA02002); Beijing Natural Science Foundation (Z131100005213003).

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015(136):359–386. [PubMed]
2. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, Van De Vijver M, Viale G. HER2 testing in gastric cancer: a practical approach. Modern Pathol. 2012(25):637–650. [PubMed]
3. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–1529. [PubMed]
4. Appert-Collin A, Hubert P, Cremel G, Bennasroune A. Role of ErbB receptors in cancer cell migration and invasion. Front Pharmacol. 2015;6:283. [PMC free article] [PubMed]
5. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303. [PMC free article] [PubMed]
6. Davidson M, Okines AF, Starling N. Current and future therapies for advanced gastric cancer. Clin Colorectal Cancer. 2015;14:239–250. [PubMed]
7. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. [PubMed]
8. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26–33. [PubMed]
9. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146:264–275. [PMC free article] [PubMed]
10. Junttila TT, Akita RW, Parsons K, Fields C, Phillips GDL, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15:429–440. [PubMed]
11. Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Brit J Cancer. 2011;105:1273–1278. [PMC free article] [PubMed]
12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. [PubMed]
13. Gomez-Martin C, Lopez-Rios F, Aparicio J, Barriuso J, Garcia-Carbonero R, Pazo R, Rivera F, Salgado M, Salud A, Vazquez-Sequeiros E, Lordick F. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. Cancer Lett. 2014;351:30–40. [PubMed]
14. Moroni M, Stella M, Pedrazzoli P, Pirovano M, Boveri E, Veronese S. c. 428T> C (p. V143A) homozygous mutation in TP53 gene as a possible mechanism of resistance to trastuzumab therapy in gastric cancer. Acta Oncol. 2016;55:1373–1375. [PubMed]
15. Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C, Shen H, Weisenberger DJ, Schultz N, Shen R, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. [PubMed]
16. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11:263–275. [PMC free article] [PubMed]
17. Gagliato DdM, Jardim D, Marchesi M, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016;7:64431–64446. doi: 10.18632/oncotarget.7043. [PMC free article] [PubMed] [Cross Ref]
18. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol. 2009;10:1179–1187. [PubMed]
19. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009;15:7479–7491. [PMC free article] [PubMed]
20. Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515–524. [PubMed]
21. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. New Engl J Med. 2007;357:39–51. [PubMed]
22. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68:5878–5887. [PubMed]
23. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100:8933–8938. [PubMed]
24. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011;17:461–469. [PMC free article] [PubMed]
25. Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, Jimenez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzman M, Gili M, Rodriguez O, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci. 2011;108:3761–3766. [PubMed]
26. Yang Z, Guo L, Liu D, Sun L, Chen H, Deng Q, Liu Y, Yu M, Ma Y, Guo N. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget. 2015;6:5072–5087. doi: 10.18632/oncotarget.3241. [PMC free article] [PubMed] [Cross Ref]
27. Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G, Simionato F, Boschi F, Zanotto M, Mina MM, Santoro R, Merz V, Sbarbati A, et al. An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients. Clin Cancer Res. 2016;22:6164–6175. [PubMed]
28. Shi M, Yang Z, Hu M, Liu D, Hu Y, Qian L, Zhang W, Chen H, Guo L, Yu M, Song L, Ma Y, Guo N. Catecholamine-induced β2-adrenergic receptor activation mediates desensitization of gastric cancer cells to Trastuzumab by upregulating MUC4 Expression. J Immunol. 2013;190:5600–5608. [PubMed]
29. Li G, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai J, Wei H, Guo Y. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget. 2014;5:8317–8329. doi: 10.18632/oncotarget.2135. [PMC free article] [PubMed] [Cross Ref]
30. Liu J, Pan C, Guo L, Wu M, Guo J, Peng S, Wu Q, Zuo Q. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway. J Hematol Oncol. 2016;9:76. [PMC free article] [PubMed]
31. Zuo Q, Liu J, Zhang J, Wu M, Guo L, Liao W. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance. Sci Rep. 2015;5:11634. [PMC free article] [PubMed]
32. Arienti C, Zanoni M, Pignatta S, Del Rio A, Carloni S, Tebaldi M, Tedaldi G, Tesei A. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. Oncotarget. 2016;7:18424–18439. doi: 10.18632/oncotarget.7575. [PMC free article] [PubMed] [Cross Ref]
33. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158:929–944. [PMC free article] [PubMed]
34. Lai M, Liang L, Chen J, Qiu N, Ge S, Ji S, Shi T, Zhen B, Liu M, Ding C, Wang Y, Qin J. Multidimensional proteomics reveals a role of UHRF2 in the regulation of epithelial-mesenchymal transition (EMT) Mol Cell Proteomics. 2016;15:2263–2278. [PMC free article] [PubMed]
35. Ding C, Jiang J, Wei J, Liu W, Zhang W, Liu M, Fu T, Lu T, Song L, Ying W, Chang C, Zhang Y, Ma J, et al. A fast workflow for identification and quantification of proteomes. Mol Cell Proteomics. 2013;12:2370–2380. [PMC free article] [PubMed]
36. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, Davies SR, Wang S, Wang P, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513:382–387. [PMC free article] [PubMed]
37. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45:D362–D368. [PMC free article] [PubMed]
38. Holt SV, Logie A, Davies BR, Alferez D, Runswick S, Fenton S, Chresta CM, Gu Y, Zhang J, Wu YL. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055) Cancer Res. 2012;72:1804–1813. [PubMed]
39. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010;70:288–298. [PubMed]
40. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia. 2012;26:1195–1202. [PubMed]
41. Asahina H, Nokihara H, Yamamoto N, Yamada Y, Tamura Y, Honda K, Seki Y, Tanabe Y, Shimada H, Shi X, Tamura T. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Invest New Drugs. 2013;31:677–684. [PubMed]
42. Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012;107:1093–1099. [PMC free article] [PubMed]
43. Larsen PB, Kümler I, Nielsen DL. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treat Rev. 2013;39:720–727. [PubMed]
44. Zazo S, Gonzalez-Alonso P, Martin-Aparicio E, Chamizo C, Cristobal I, Arpi O, Rovira A, Albanell J, Eroles P, Lluch A, Madoz-Gurpide J, Rojo F. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. Am J Cancer Res. 2016;6:2661–2678. [PMC free article] [PubMed]
45. Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci. 2015;36:124–135. [PubMed]
46. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293. [PMC free article] [PubMed]
47. Alajati A, Guccini I, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, Montani E, Rinaldi A, Montemurro F, Catapano C, Bertoni F, Alimonti A. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. Cell Rep. 2015;11:564–576. [PubMed]
48. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6:11652–11663. doi: 10.18632/oncotarget.3457. [PMC free article] [PubMed] [Cross Ref]
49. Zhou H, Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci. 2011;12:30–42. [PMC free article] [PubMed]
50. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10:1597–1606. [PMC free article] [PubMed]
51. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–362. [PubMed]
52. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature. 2011;473:337–342. [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC